NLC Health Impact Fund backs medtech innovation Amotio to transform revision joint surgeries with a GBP 210,000 investment
NLC Health Impact Fund has invested GBP 210,000 in Amotio Health as part of an GBP 810,000 pre-seed round, supporting the development of Amotio’s novel technology for improving outcomes in complex orthopaedic revision surgeries.
Founded within the NLC Venture Building ecosystem, Amotio is addressing the critical unmet need of safe and efficient removal of surgical cement during joint revision operations. The technology, developed by surgeons and engineers at Utrecht University Hospital, combines 3D printing, high-speed cutting tools, and digital surgical planning to deliver patient-specific, precision-engineered solutions for cement removal.
The current standard of care in revision hip surgeries often involves labourious, high-risk manual removal of bone cement, contributing to prolonged operating times, complications, and delayed patient recovery. Amotio’s system integrates a customised surgical cutting guide with a high-speed burr to enable targeted, controlled cement extraction while preserving healthy bone - reducing surgical complexity, blood loss, and overall rehabilitation time.
The GBP 810,000 investment round was led by the Development Bank of Wales with GBP 500,000, including backing from the Technology Seed Fund and the Wales Flexible Investment Fund. NLC Health Ventures contributed GBP 210,000 through its Health Impact Fund, alongside specialist investors Orthopaedic Research UK.
Dr Harry George, Assistant Investment Executive in the Technology Ventures Investment team at the Development Bank of Wales, said: “We’re glad to have been joined by NLC Health Ventures in this investment round for Amotio. Attracting private sector funding into Wales is a key tool for unlocking ambition and driving long-term sustainable growth, which is why we work hard to identify and nurture co-investment alongside specialist funders like NLC.” This marks a significant milestone in Amotio’s journey, which began with its discovery and development at NLC.
The venture has since progressed through NLC’s venture building process, having received the initial discovery investment, secured over GBP 400,000 in grants from Innovate UK and the Welsh Government, and assembled a dedicated product development team with offices and lab facilities now operational in Wales.
“As the largest early-stage healthcare venture builder in Europe, NLC exists to bring impactful technologies to life by supporting exceptional entrepreneurs and connecting them with strategic capital,” said Margarida Lopes, Investment Associate. “Amotio exemplifies this mission - tackling a clear, global clinical challenge with an innovative, scalable solution that has potential to dramatically improve surgical outcomes for thousands of patients.”
The investment will enable Amotio to complete product development, reach design freeze, and prepare for preclinical testing and regulatory pathways in key markets, including Europe, the US, and Asia-Pacific.
Amotio’s CEO, Iestyn Foster, added: “Navigating early-stage medtech funding is notoriously difficult, but with the support of the Development Bank of Wales, NLC, Orthopaedic Research UK, and our broader ecosystem in South Wales and Europe, we’re positioned to accelerate development and bring our technology to patients in need of safer, more effective joint revision procedures.”
Kim High, Venture Partner and Lead of the OrthoSpine Business Unit at NLC, said: "It's been inspiring to see Amotio evolve from a promising surgical concept, driven by the needs of surgeons, into a robust, real-world solution. This investment isn't just a validation of the immense opportunity Amotio offers, it's a recognition of the dedicated team poised to revolutionise revision joint surgeries. As a co-founding partner, NLC is immensely proud to have helped bring this innovation to life, and we eagerly anticipate their accelerated journey towards improving patient care globally."
About NLC Health Ventures
NLC Health Ventures is Europe’s leading early-stage healthcare investor and venture builder, with a mission to bring science-based health innovations to life. Through its specialised funds, including the Health Impact Fund, NLC invests in scalable, impactful ventures that address pressing global healthcare challenges.
For more information:
Iestyn Foster, CEO
Amotio Health Ltd.
Follow the company on LinkedIn:
https://www.linkedin.com/company/amotio/
%2520980x600.jpeg)
.webp)
